Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bayer decides to withdraw cholesterol lowering drug.

× No keyword cloud information.

16 in total

1. Should drug companies be allowed to talk directly to patients? NO.

Authors: Wendy Garlick
Journal: BMJ Date: 2003-06-14

2. A pharmacoepidemiological network model for drug safety surveillance: statins and rhabdomyolysis.

Authors: Ben Y Reis; Karen L Olson; Lu Tian; Rhonda L Bohn; John S Brownstein; Peter J Park; Mark J Cziraky; Marcus D Wilson; Kenneth D Mandl
Journal: Drug Saf Date: 2012-05-01 Impact factor: 5.606

3. Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study.

Authors: Tuire Tirkkonen; Anna Ryynänen; Tero Vahlberg; Kerttu Irjala; Timo Klaukka; Risto Huupponen; Kari Laine
Journal: Drug Saf Date: 2008 Impact factor: 5.606

Review 4. Today's challenges in pharmacovigilance: what can we learn from epoetins?

Authors: Hans C Ebbers; Aukje K Mantel-Teeuwisse; Ellen H M Moors; Huub Schellekens; Hubert G Leufkens
Journal: Drug Saf Date: 2011-04-01 Impact factor: 5.606

5. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.

Authors: Keith B Hoffman; Mo Dimbil; Nicholas P Tatonetti; Robert F Kyle
Journal: Drug Saf Date: 2016-06 Impact factor: 5.606

Review 6. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors: David Williams; John Feely
Journal: Clin Pharmacokinet Date: 2002 Impact factor: 6.447

7. Transporters in Regulatory Science: Notable Contributions from Dr. Giacomini in the Past Two Decades.

Authors: Lei Zhang; Qi Liu; Shiew-Mei Huang; Robert Lionberger
Journal: Drug Metab Dispos Date: 2022-06-29 Impact factor: 3.579

8. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone.

Authors: Yoon K Loke; Sheena Derry; Jeffrey K Aronson
Journal: Br J Clin Pharmacol Date: 2004-05 Impact factor: 4.335

Review 9. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.

Authors: Abril Verden; Mo Dimbil; Robert Kyle; Brian Overstreet; Keith B Hoffman
Journal: Drug Saf Date: 2018-04 Impact factor: 5.606

Review 10. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents.

Authors: Michael Tatley; Ruth Savage
Journal: Drug Saf Date: 2007 Impact factor: 5.606